Research graph
References from Targeting the metabolic-immune regulator SLC35F6 enhances temozolomide and anti-PD-L1 therapy in glioma. Local targets link to admitted publications; unresolved targets remain external evidence.
Prickle4 drives microenvironmental remodeling and resistance to parp inhibition in IDH-mutant glioma
10.1002/advs.202503866 · 2026 · External reference
TENT5A increases glioma malignancy and promotes its progression
10.2174/0115748928280901231206102637 · 2025 · External reference
Aberrant PLAC8 expression characterizes glioblastoma with temozolomide resistance and an immunosuppressive microenvironment
10.1016/j.canlet.2025.217805 · 2025 · External reference
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma
10.1016/j.drup.2024.101122 · 2024 · External reference
Primary brain tumours in adults
10.1016/s0140-6736(23)01054-1 · 2023 · External reference
In vitro models of the interplay between glioblastoma and blood-brain barrier for stratifying drug efficacy
10.1016/j.addr.2025.115702 · 2025 · External reference
The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma
10.1186/s13046-024-03175-9 · 2024 · External reference
Generation and validation of a novel multitarget small molecule in glioblastoma
10.1038/s41419-025-07569-1 · 2025 · External reference
Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers
10.1016/j.jconrel.2022.03.019 · 2022 · External reference
Circular RNA NF1-419 inhibits proliferation and induces apoptosis by regulating lipid metabolism in astroglioma cells
10.2174/1574892816666210729125802 · 2022 · External reference
Impact of epigenetic reprogramming on antitumor immune responses in glioma
10.1172/jci163450 · 2023 · External reference
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
10.1016/j.ccell.2022.07.011 · 2022 · External reference
Metal-based nanomaterials achieve tumor treatment strategies by overcoming the blood-brain barrier of glioma and responding to the tumor microenvironment
2026 · External reference
Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
10.1186/s13046-021-02078-3 · 2021 · External reference
Predictive and prognostic value of a glucose metabolism disorder and immune-related gene signature in glioma
10.1016/j.neuroscience.2025.12.046 · 2026 · External reference
Cancer signaling drives cancer metabolism: AKT and the warburg effect
10.1158/0008-5472.can-21-2647 · 2021 · External reference
NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas
10.1038/s41419-020-2520-2 · 2020 · External reference
Glucose oxidase-powered nanocatalytic medicine: rewiring tumor metabolism for multimodal cancer therapy
2026 · External reference
Homeobox A3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression
10.1093/neuonc/noac231 · 2023 · External reference
Endothelial cells sense temozolomide resistance to facilitate monocyte-derived macrophage infiltration in glioblastoma
10.1016/j.drup.2025.101329 · 2026 · External reference
Unveiling the role of TAM-derived extracellular vesicles in glioma progression through Treg polarization and immune suppression
10.1038/s41388-025-03497-8 · 2025 · External reference
Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma
10.1038/s41419-026-08701-5 · 2026 · External reference
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
10.1186/s12943-023-01725-x · 2023 · External reference
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
10.1172/jci163446 · 2023 · External reference
The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism
10.1038/s41698-025-01198-9 · 2026 · External reference
Roles and therapeutic targeting of SLC transporters in gastrointestinal malignancies
10.1016/j.canlet.2025.218222 · 2026 · External reference
Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma
10.1186/s13000-024-01582-2 · 2024 · External reference
Residence of the nucleotide sugar transporter family members SLC35F1 and SLC35F6 in the endosomal/lysosomal pathway
10.3390/ijms25126718 · 2024 · External reference
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
10.1093/neuonc/noad100 · 2023 · External reference
Basic transcription factor 3 like 4 enhances malignant phenotypes through modulating tumor cell function and immune microenvironment in Glioma
10.1016/j.ajpath.2024.01.011 · 2024 · External reference
KRTCAP2 accelerates malignant progression through modulating tumor cell function and M2 macrophage infiltration in glioma
2026 · External reference
Advances in the optimization of central carbon metabolism in metabolic engineering
10.1186/s12934-023-02090-6 · 2023 · External reference
Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer
2025 · External reference
Metabolism, metabolites, and macrophages in cancer
10.1186/s13045-023-01478-6 · 2023 · External reference
Multifunctional copper-light synergistic prodrug nanosystems for specific reprogramming of tumour immunogenic endoplasmic reticulum stress
10.1016/j.biomaterials.2025.123625 · 2026 · External reference
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
10.1038/s41467-024-44963-3 · 2024 · External reference
Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-Kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial
10.1200/jco.18.01207 · 2019 · External reference
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma
10.1093/neuonc/nox044 · 2017 · External reference
Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop
2026 · External reference
Dual‐Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy
10.1002/adma.202400502 · 2024 · External reference
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
10.1038/s41568-019-0216-7 · 2020 · External reference
Glutamate dehydrogenase 1-catalytic glutaminolysis feedback activates EGFR/PI3K/AKT pathway and reprograms glioblastoma metabolism
10.1093/neuonc/noae222 · 2025 · External reference
A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism
10.1016/j.celrep.2024.114119 · 2024 · External reference
Phagocytosis of glioma cells enhances the immunosuppressive phenotype of bone marrow-derived macrophages
10.1158/0008-5472.can-22-1570 · 2023 · External reference
CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma
10.1093/neuonc/noaf157 · 2025 · External reference
Single-cell deconstruction of medulloblastoma microenvironment elucidates subtype-specific immune architectures and prognostic molecular signatures
10.1016/j.canlet.2025.218126 · 2026 · External reference
Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma
10.1016/j.celrep.2023.112197 · 2023 · External reference
Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab
10.1016/j.intimp.2024.112187 · 2024 · External reference
Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy
2025 · External reference
Blood-brain barrier conquest in glioblastoma nanomedicine: strategies, clinical advances, and emerging challenges
10.3390/cancers16193300 · 2024 · External reference
Brain-targeted drug delivery by in vivo functionalized liposome with stable D-peptide ligand
10.1016/j.jconrel.2024.07.014 · 2024 · External reference
Tuning lipid nanocarrier mechanical properties to improve glioblastoma targeting and blood brain barrier penetration
10.1039/d5nr00984g · 2025 · External reference
Extracellular vesicles in nanomedicine and regenerative medicine: a review over the last decade
2024 · External reference
Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases
10.1186/s40035-024-00453-6 · 2024 · External reference
Transferrin-conjugated PLGA nanoparticles for Co-Delivery of temozolomide and bortezomib to glioblastoma cells
10.1021/acsanm.3c02122 · 2023 · External reference
Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides
10.1002/jev2.12255 · 2022 · External reference
Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma
10.1038/s41388-025-03454-5 · 2025 · External reference
